

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM398740

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Hedgepath Pharmaceuticals, Inc.		09/22/2015	Corporation: FLORIDA
RECEIVING PARTY DATA			
Name:	Mayne Pharma International Pty Ltd		
Street Address:	474 Flinders Street		
Internal Address:	Level 14		
City:	Melbourne, VIC		
State/Country:	AUSTRALIA		
Postal Code:	3000		
Entity Type:	Company: AUSTRALIA		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	86457412	SUBITRA	
CORRESPONDENCE DATA			
Fax Number:	3523725800		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	352-375-8100		
Email:	ckc@slepatents.com		
Correspondent Name:	Corey K. Cho		
Address Line 1:	3107 S.W. Williston Road		
Address Line 4:	Gainesville, FLORIDA 32608		
DOMESTIC REPRESENTATIVE			
Name:	Corey K. Cho		
Address Line 1:	3107 S.W. Williston Road		
Address Line 4:	Gainesville, FLORIDA 32608		
NAME OF SUBMITTER:	Corey K. Cho		
SIGNATURE:	/corey k cho/		
DATE SIGNED:	09/16/2016		

OP \$40.00 86457412

Total Attachments: 1

source=2177159-Assignment-fully_signed#page1.tif

TRADEMARK ASSIGNMENT

Dated effective as of: September 22, 2015

WHEREAS, Hedgepath Pharmaceuticals, Inc., a Florida Corporation, of 324 S. Hyde Park Avenue, Suite 350 Tampa FLORIDA 33606 ("Assignor") has adopted and owns the Mark SUBITRA (the "Mark") in connection with the following goods and/or services: Pharmaceutical products for the prevention and treatment of cancer; and

WHEREAS, Assignor has applied to register the Mark on the Principal Register of the United States Patent and Trademark Office in connection with the above-described goods and/or services, Application Serial No. 86457412 filed on November 18th 2014; and

WHEREAS, Mayne Pharma International Pty Ltd (ACN 007 870 984), Level 14, 474 Flinders Street, Melbourne VIC 3000 Australia ("Assignee"), desires to acquire the Mark as a successor to the portion of the Assignor's business to which the Mark pertains, and that business is ongoing and existing.

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby sells, assigns and transfers to Assignee all right, title and interest in and to the Mark, in the United States and abroad, together with the goodwill of the business symbolized by the Mark, and the pending application for registration.

Hedgepath Pharmaceuticals, Inc.,

By: 

Name: NICHOLAS J. VUJCA

Title: PRESIDENT & CEO

Mayne Pharma International Pty Ltd

By: 

Name: KATE RINTALL

Title: VP & GENERAL COUNSEL